TR201900148T4 - 2,4 diamino-quinoline substituted as novel agents against cancer. - Google Patents
2,4 diamino-quinoline substituted as novel agents against cancer. Download PDFInfo
- Publication number
- TR201900148T4 TR201900148T4 TR2019/00148T TR201900148T TR201900148T4 TR 201900148 T4 TR201900148 T4 TR 201900148T4 TR 2019/00148 T TR2019/00148 T TR 2019/00148T TR 201900148 T TR201900148 T TR 201900148T TR 201900148 T4 TR201900148 T4 TR 201900148T4
- Authority
- TR
- Turkey
- Prior art keywords
- diamino
- against cancer
- agents against
- novel agents
- quinoline substituted
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- NKXSJFUIFJMXED-UHFFFAOYSA-N quinoline-2,4-diamine Chemical group C1=CC=CC2=NC(N)=CC(N)=C21 NKXSJFUIFJMXED-UHFFFAOYSA-N 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical group C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Bu buluş yeni 2-primer amino-4-sekonder amino-kinolin türevlerine, bunların imalatına, bunları içeren farmasötik bileşimlere ve bunların ilaçlar olarak kullanımına ilişkindir. Bu buluşun etken bileşikleri proliferatif neoplastik ve neoplastik olmayan hastalıkların tedavisi ve önlenmesi için yararlıdır.The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful for the treatment and prevention of proliferative neoplastic and non-neoplastic diseases.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462073325P | 2014-10-31 | 2014-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201900148T4 true TR201900148T4 (en) | 2019-02-21 |
Family
ID=55404745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/00148T TR201900148T4 (en) | 2014-10-31 | 2015-10-26 | 2,4 diamino-quinoline substituted as novel agents against cancer. |
Country Status (34)
Country | Link |
---|---|
US (1) | US10722505B2 (en) |
EP (1) | EP3212629B1 (en) |
JP (1) | JP6588546B2 (en) |
KR (1) | KR102548547B1 (en) |
CN (1) | CN107148416B (en) |
AU (1) | AU2015338844B2 (en) |
CA (1) | CA2965262C (en) |
CL (1) | CL2017001073A1 (en) |
CO (1) | CO2017007325A2 (en) |
CR (1) | CR20170177A (en) |
CY (1) | CY1121326T1 (en) |
DK (1) | DK3212629T3 (en) |
DO (1) | DOP2017000107A (en) |
EA (1) | EA037119B1 (en) |
EC (1) | ECSP17026748A (en) |
ES (1) | ES2707125T3 (en) |
GE (1) | GEP20207108B (en) |
HR (1) | HRP20190107T1 (en) |
IL (1) | IL251775B (en) |
LT (1) | LT3212629T (en) |
MA (1) | MA40875B1 (en) |
MY (1) | MY193740A (en) |
NI (1) | NI201700052A (en) |
PE (1) | PE20191142A1 (en) |
PH (1) | PH12017500810A1 (en) |
PL (1) | PL3212629T3 (en) |
PT (1) | PT3212629T (en) |
RS (1) | RS58328B1 (en) |
SG (1) | SG11201703479SA (en) |
SI (1) | SI3212629T1 (en) |
TN (1) | TN2017000168A1 (en) |
TR (1) | TR201900148T4 (en) |
UA (1) | UA122062C2 (en) |
WO (1) | WO2016067112A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3452465T3 (en) * | 2016-05-04 | 2021-02-08 | Genoscience Pharma | SUBSTITUTED 2,4-DIAMINOQUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES |
US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
TWI826690B (en) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | Substituted eneoxindoles and uses thereof |
WO2022033459A1 (en) * | 2020-08-10 | 2022-02-17 | 萧乃文 | Use of double non-oncology drug in preparation of pharmaceutical composition for treating cancers |
CN112375081B (en) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | Pyrrole [2,3-d ] pyrimidine derivative with CDK4, 6 or 9 inhibiting activity and preparation method and application thereof |
CN112876673B (en) * | 2021-01-25 | 2021-12-24 | 山东大学 | PH-responsive nano copolymer carrier and preparation method and application thereof |
EP4349336A1 (en) | 2022-10-04 | 2024-04-10 | Genoscience Pharma | Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8580301A1 (en) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS |
US7759336B2 (en) * | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
MXPA05009722A (en) * | 2003-03-10 | 2006-03-09 | Schering Corp | Heterocyclic kinase inhibitors: methods of use and synthesis. |
ME03780B (en) * | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
SG11201506385WA (en) * | 2013-03-18 | 2015-10-29 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
-
2015
- 2015-10-26 RS RS20190110A patent/RS58328B1/en unknown
- 2015-10-26 PT PT15837091T patent/PT3212629T/en unknown
- 2015-10-26 WO PCT/IB2015/002438 patent/WO2016067112A1/en active Application Filing
- 2015-10-26 LT LTEP15837091.6T patent/LT3212629T/en unknown
- 2015-10-26 SG SG11201703479SA patent/SG11201703479SA/en unknown
- 2015-10-26 MA MA40875A patent/MA40875B1/en unknown
- 2015-10-26 AU AU2015338844A patent/AU2015338844B2/en active Active
- 2015-10-26 DK DK15837091.6T patent/DK3212629T3/en active
- 2015-10-26 MY MYPI2017000628A patent/MY193740A/en unknown
- 2015-10-26 EA EA201790949A patent/EA037119B1/en unknown
- 2015-10-26 GE GEAP201514494A patent/GEP20207108B/en unknown
- 2015-10-26 ES ES15837091T patent/ES2707125T3/en active Active
- 2015-10-26 US US15/543,504 patent/US10722505B2/en active Active
- 2015-10-26 CR CR20170177A patent/CR20170177A/en unknown
- 2015-10-26 EP EP15837091.6A patent/EP3212629B1/en active Active
- 2015-10-26 TN TN2017000168A patent/TN2017000168A1/en unknown
- 2015-10-26 CN CN201580058830.2A patent/CN107148416B/en active Active
- 2015-10-26 KR KR1020177013639A patent/KR102548547B1/en active IP Right Grant
- 2015-10-26 CA CA2965262A patent/CA2965262C/en active Active
- 2015-10-26 UA UAA201705278A patent/UA122062C2/en unknown
- 2015-10-26 SI SI201530566T patent/SI3212629T1/en unknown
- 2015-10-26 TR TR2019/00148T patent/TR201900148T4/en unknown
- 2015-10-26 PL PL15837091T patent/PL3212629T3/en unknown
- 2015-10-26 JP JP2017522809A patent/JP6588546B2/en active Active
-
2017
- 2017-04-18 IL IL251775A patent/IL251775B/en active IP Right Grant
- 2017-04-27 DO DO2017000107A patent/DOP2017000107A/en unknown
- 2017-04-28 NI NI201700052A patent/NI201700052A/en unknown
- 2017-04-28 EC ECIEPI201726748A patent/ECSP17026748A/en unknown
- 2017-04-28 CL CL2017001073A patent/CL2017001073A1/en unknown
- 2017-05-02 PH PH12017500810A patent/PH12017500810A1/en unknown
- 2017-07-24 CO CONC2017/0007325A patent/CO2017007325A2/en unknown
- 2017-08-31 PE PE2017001484A patent/PE20191142A1/en unknown
-
2019
- 2019-01-17 HR HRP20190107TT patent/HRP20190107T1/en unknown
- 2019-01-17 CY CY20191100067T patent/CY1121326T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201900148T4 (en) | 2,4 diamino-quinoline substituted as novel agents against cancer. | |
CL2018003701A1 (en) | Heterocyclic compounds as immunomodulators. | |
MX2015013396A (en) | Quinolines derivatives as novel anticancer agents. | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
UA116648C2 (en) | FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES | |
PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
TR201819138T4 (en) | Quinoxaline Derivatives Useful as FGFR Kinase Modulators | |
EA201692301A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
MX2015008957A (en) | Fluoro-[1,3]oxazines as bace1 inhibitors. | |
CL2016002091A1 (en) | Triazine compound and its use for medicinal purposes | |
TW201613864A (en) | Novel compounds | |
PH12015502365B1 (en) | Bace1 inhibitors | |
TR201908265T4 (en) | Fused 1,4-dihydrodioxine derivatives as inhibitors of heat shock transcription factor 1. | |
PL410665A1 (en) | Arginase inhibitors and their therapeutical applications | |
TR201900659T4 (en) | Benzoxazinone amides as mineralocorticoid receptor modulators. | |
EA201790070A1 (en) | BIPHENYLAMIDE CONTAINING MODIFIED SIMPLE ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 STIMULATORS | |
MX2019001634A (en) | Amide compounds, pharmaceutical compositions thereof, and methods of using the same. | |
PH12017501668A1 (en) | Bace1 inhibitors | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
EA201891680A1 (en) | INDAN DERIVATIVES AS MGLUR7 MODULATORS | |
MX2016016061A (en) | 2,2,2-trifluoroethyl-thiadiazines. | |
EA201892188A1 (en) | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS |